AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 33559842 — intervention group
Group type: EXPERIMENTAL
Intervention: Twice-weekly 25-mg prefilled liquid Yisaipu (group I)
Number of subjects: 640
Study 33559842 — intervention group
Group type: EXPERIMENTAL
Intervention: Once-weekly 50-mg prefilled liquid Yisaipu (group II)
Number of subjects: 640
Study 33559842 — intervention group
Group type: COMPARATOR
Intervention: Twice-weekly 25-mg lyophilized Yisaipu (group III)
Number of subjects: 640
Study 33559842 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 640
Study 33560090 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus
Number of subjects: 712
Study 33560090 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 712
Study 33560097 — intervention group
Group type: EXPERIMENTAL
Intervention: Micafungin 150 mg loading dose followed by 100 mg daily
Number of subjects: 16
Study 33560097 — intervention group
Group type: COMPARATOR
Intervention: Micafungin 100 mg daily
Number of subjects: 16
Study 33560097 — intervention group
Group type: COMPARATOR
Intervention: CVVH
Number of subjects: 16
Study 33560097 — intervention group
Group type: COMPARATOR
Intervention: CVVHDF
Number of subjects: 16
Study 33560234 — intervention group
Group type: EXPERIMENTAL
Intervention: IDEAL CGM web-based training intervention
Number of subjects: 8
Study 33560234 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced standard care plus IDEAL CGM intervention
Number of subjects: 8
Study 33560234 — intervention group
Group type: COMPARATOR
Intervention: Enhanced standard care
Number of subjects: 8
Study 33560240 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated Engagement Support System
Number of subjects: 27
Study 33560240 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 27
Study 33560372 — intervention group
Group type: EXPERIMENTAL
Intervention: Low caloric diet (LCD; 800 kcal/d) in DiOGenes study
Number of subjects: 261
Study 33560372 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight maintenance following LCD in DiOGenes study
Number of subjects: 261
Study 33560372 — intervention group
Group type: EXPERIMENTAL
Intervention: Low caloric diet (LCD; 800-1000 kcal/d) in Finnish CRYO study
Number of subjects: 261
Study 33560372 — intervention group
Group type: EXPERIMENTAL
Intervention: Roux-en-Y gastric bypass (RYGB) surgery in KOBS study
Number of subjects: 261
Study 33560372 — intervention group
Group type: EXPERIMENTAL
Intervention: Roux-en-Y gastric bypass (RYGB) surgery in DEOSH study (2-year follow-up)
Number of subjects: 261
Study 33560372 — intervention group
Group type: EXPERIMENTAL
Intervention: Roux-en-Y gastric bypass (RYGB) surgery in DEOSH study (5-year follow-up)
Number of subjects: 261
Study 33560372 — intervention group
Group type: EXPERIMENTAL
Intervention: Roux-en-Y gastric bypass (RYGB) surgery (proteomics level)
Number of subjects: 261
Study 33560375 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiagent initial chemotherapy
Number of subjects: 235
Study 33560375 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiagent initial chemotherapy with anthracycline and etoposide
Number of subjects: 235
Study 33560375 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous hematopoietic cell transplantation
Number of subjects: 235
Study 33560384 — intervention group
Group type: COMPARATOR
Intervention: Denosumab
Number of subjects: 1718
Study 33560384 — intervention group
Group type: COMPARATOR
Intervention: Denosumab (ASCT-intent subgroup, frontline triplet)
Number of subjects: 1718
Study 33560384 — intervention group
Group type: COMPARATOR
Intervention: Denosumab (ASCT-intent subgroup, bortezomib-only)
Number of subjects: 1718
Study 33560394 — intervention group
Group type: EXPERIMENTAL
Intervention: IV copanlisib 60 mg on days 1, 8, and 15 of 28-day cycles for a median of 23 weeks
Number of subjects: 23
Study 33560399 — intervention group
Group type: EXPERIMENTAL
Intervention: Omidubicel in combination with unmanipulated UCB graft
Number of subjects: 16
Study 33560399 — intervention group
Group type: EXPERIMENTAL
Intervention: Single omidubicel graft
Number of subjects: 16
Study 33560404 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiogenic Shock (CS) patients
Number of subjects: 4856
Study 33560404 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk factors for developing CS
Number of subjects: 4856
Study 33560404 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk factors for mortality
Number of subjects: 4856
Study 33560478 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiation therapy
Number of subjects: 0
Study 33560478 — intervention group
Group type: COMPARATOR
Intervention: Concurrent chemotherapy
Number of subjects: 0
Study 33560478 — intervention group
Group type: COMPARATOR
Intervention: Advanced testing using next-generation sequencing
Number of subjects: 0
Study 33560583 — intervention group
Group type: EXPERIMENTAL
Intervention: Foot orthoses for 6 months
Number of subjects: 6
Study 33560746 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention not specified; details not available.
Number of subjects: 0
Study 33560866 — intervention group
Group type: EXPERIMENTAL
Intervention: Isokinetic strength testing and 3-dimensional biomechanical analysis of jump and change-of-direction tests 9 months after ACLR
Number of subjects: 1045
Study 33560866 — intervention group
Group type: EXPERIMENTAL
Intervention: Quadriceps strength and plyometric ability targeting during late-stage rehabilitation
Number of subjects: 1045
Study 33560866 — intervention group
Group type: COMPARATOR
Intervention: Patient-reported outcomes, limb symmetry of clinical performance measures, and biomechanical measures in change-of-direction tasks
Number of subjects: 1045
Study 33560905 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapid-EEG
Number of subjects: 0
Study 33560905 — intervention group
Group type: COMPARATOR
Intervention: Clinical suspicion alone
Number of subjects: 0
Study 33561010 — intervention group
Group type: EXPERIMENTAL
Intervention: CRISPR-augmented RT-PCR assay
Number of subjects: 159
Study 33561010 — intervention group
Group type: COMPARATOR
Intervention: RT-qPCR nasal/nasopharyngeal test
Number of subjects: 159
Study 33561011 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin deprivation for 5.4 ± 0.6 hours in T1D participants
Number of subjects: 28
Study 33561011 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin deprivation in T1D participants
Number of subjects: 28
Study 33561011 — intervention group
Group type: COMPARATOR
Intervention: Baseline comparison with ND participants
Number of subjects: 28
Study 33561018 — intervention group
Group type: EXPERIMENTAL
Intervention: Development of an exhaustive list of health-related quality of life (HRQoL) issues relevant to sarcoma patients and determination of content validity.
Number of subjects: 0
Study 33561018 — intervention group
Group type: EXPERIMENTAL
Intervention: Strategy for HRQoL measurement in sarcoma patients.
Number of subjects: 0
Study 33561122 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole egg consumption (additional half of a whole egg per day)
Number of subjects: 521120
Study 33561122 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary cholesterol intake (additional 300 mg per day)
Number of subjects: 521120
Study 33561122 — intervention group
Group type: COMPARATOR
Intervention: Egg white/substitute consumption
Number of subjects: 521120
Study 33561122 — intervention group
Group type: COMPARATOR
Intervention: Replacing half a whole egg with egg whites/substitutes or other protein sources
Number of subjects: 521120
Study 33561169 — intervention group
Group type: EXPERIMENTAL
Intervention: Low birth weight (LBW) infants
Number of subjects: 907
Study 33561169 — intervention group
Group type: EXPERIMENTAL
Intervention: Preterm birth
Number of subjects: 907
Study 33561262 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetuximab plus S-1 plus cisplatin
Number of subjects: 40
Study 33561615 — intervention group
Group type: EXPERIMENTAL
Intervention: Appropriate-fitting footwear
Number of subjects: 153
Study 33561615 — intervention group
Group type: COMPARATOR
Intervention: Ill-fitting footwear
Number of subjects: 153
Study 33562091 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifamycin SV, 600 mg modified release tablets, taken three times a day for 14 days (total daily intake: 1800 mg)
Number of subjects: 18
Study 33562419 — intervention group
Group type: EXPERIMENTAL
Intervention: Passive microwave radiometry (MWR)
Number of subjects: 0
Study 33562419 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy individuals)
Number of subjects: 0
Study 33562569 — intervention group
Group type: EXPERIMENTAL
Intervention: let-7b-5p levels in cerebrospinal fluid (CSF)
Number of subjects: 0
Study 33563002 — intervention group
Group type: EXPERIMENTAL
Intervention: Obesity
Number of subjects: 4200
Study 33563015 — intervention group
Group type: EXPERIMENTAL
Intervention: Thrombectomy plus standard care
Number of subjects: 293
Study 33563015 — intervention group
Group type: COMPARATOR
Intervention: Standard care alone
Number of subjects: 293
Study 33563242 — intervention group
Group type: EXPERIMENTAL
Intervention: Real-time fMRI neurofeedback from the hippocampus
Number of subjects: 84
Study 33563242 — intervention group
Group type: COMPARATOR
Intervention: Real-time fMRI neurofeedback from a functionally independent region
Number of subjects: 84
Study 33563263 — intervention group
Group type: EXPERIMENTAL
Intervention: Difficulty engaging with doctors (1-4; higher score = greater difficulty)
Number of subjects: 304
Study 33563263 — intervention group
Group type: EXPERIMENTAL
Intervention: Difficulty engaging with doctors
Number of subjects: 304
Study 33563263 — intervention group
Group type: EXPERIMENTAL
Intervention: LEP status (yes vs. no)
Number of subjects: 304
Study 33563768 — intervention group
Group type: EXPERIMENTAL
Intervention: Universal germline testing for cancer susceptibility genes
Number of subjects: 486
Study 33563768 — intervention group
Group type: EXPERIMENTAL
Intervention: Broad panel including genes from the additional testing set
Number of subjects: 486
Study 33563776 — intervention group
Group type: EXPERIMENTAL
Intervention: Health-related quality of life (HRQoL) assessed using the EuroQol-5 dimension (EQ-5D) questionnaire at enrolment and 6-month intervals.
Number of subjects: 9126
Study 33563894 — intervention group
Group type: EXPERIMENTAL
Intervention: Panobinostat (10 or 15 mg), lenalidomide 15 mg, bortezomib 1 mg/m²
Number of subjects: 20
Study 33564263 — intervention group
Group type: EXPERIMENTAL
Intervention: Elagolix 150 mg once daily (QD)
Number of subjects: 1686
Study 33564263 — intervention group
Group type: EXPERIMENTAL
Intervention: Elagolix 200 mg twice daily (BID)
Number of subjects: 1686
Study 33564263 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1686
Study 33564311 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined external cold and vibrating devices
Number of subjects: 0
Study 33564311 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard procedure)
Number of subjects: 0
Study 33565026 — intervention group
Group type: EXPERIMENTAL
Intervention: Lasmiditan 100 mg (Cohort 1)
Number of subjects: 18
Study 33565026 — intervention group
Group type: EXPERIMENTAL
Intervention: Lasmiditan 200 mg (Cohort 2)
Number of subjects: 18
Study 33565026 — intervention group
Group type: EXPERIMENTAL
Intervention: Lasmiditan (both cohorts)
Number of subjects: 18
Study 33565042 — intervention group
Group type: EXPERIMENTAL
Intervention: Meropenem-vaborbactam (M-V)
Number of subjects: 0
Study 33565042 — intervention group
Group type: COMPARATOR
Intervention: Best available treatment (BAT)
Number of subjects: 0
Study 33565427 — intervention group
Group type: EXPERIMENTAL
Intervention: Radical prostatectomy
Number of subjects: 1343
Study 33565790 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-acute pancreatitis pancreatic exocrine insufficiency (PEI) assessment using fecal elastase-1
Number of subjects: 77
Study 33565790 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up at 3 months
Number of subjects: 77
Study 33565790 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up at 12 months
Number of subjects: 77
Study 33565964 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcriptional changes associated with multiple epidemiologic risk factors in cord blood mononuclear cells.
Number of subjects: 0
Study 33565964 — intervention group
Group type: EXPERIMENTAL
Intervention: Umbilical cord blood serum concentration of PGLYRP-1.
Number of subjects: 0
Study 33566467 — intervention group
Group type: EXPERIMENTAL
Intervention: Urinary (tissue inhibitor of metalloproteinases-2) × (insulin-like growth factor binding protein 7) test
Number of subjects: 723
Study 33566729 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetes technology use
Number of subjects: 0
Study 33566729 — intervention group
Group type: EXPERIMENTAL
Intervention: HbA1c levels
Number of subjects: 0
Study 33567087 — intervention group
Group type: EXPERIMENTAL
Intervention: SARS-CoV-2-specific antibodies testing using VITROS Anti-SARS-CoV-2 IgG test
Number of subjects: 566
Study 33567087 — intervention group
Group type: EXPERIMENTAL
Intervention: Symptoms of anosmia/ageusia
Number of subjects: 566
Study 33567087 — intervention group
Group type: EXPERIMENTAL
Intervention: Symptoms of chest congestion
Number of subjects: 566
Study 33567087 — intervention group
Group type: EXPERIMENTAL
Intervention: Symptoms of fever
Number of subjects: 566
Study 33567087 — intervention group
Group type: EXPERIMENTAL
Intervention: Symptoms of shortness of breath
Number of subjects: 566
Study 33567087 — intervention group
Group type: EXPERIMENTAL
Intervention: Previous RT-PCR testing
Number of subjects: 566
Study 33567109 — intervention group
Group type: EXPERIMENTAL
Intervention: Benzodiazepines (lorazepam, midazolam, diazepam)
Number of subjects: 460
Study 33567192 — intervention group
Group type: EXPERIMENTAL
Intervention: Unilateral vestibular implant (prosthesis)
Number of subjects: 9
Study 33567333 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftolozane/Tazobactam (C/T) 3 g (ceftolozane 2 g/tazobactam 1 g) as a 60-minute intravenous infusion
Number of subjects: 11
Study 33568007 — intervention group
Group type: EXPERIMENTAL
Intervention: EndoAnchors
Number of subjects: 221
Study 33568158 — intervention group
Group type: EXPERIMENTAL
Intervention: High intake of vegetables
Number of subjects: 986
Study 33568158 — intervention group
Group type: EXPERIMENTAL
Intervention: Mediation by gut microbiome (Collinsella)
Number of subjects: 986
Study 33568158 — intervention group
Group type: EXPERIMENTAL
Intervention: Habitual diet high in vegetables
Number of subjects: 986
Study 33568158 — intervention group
Group type: COMPARATOR
Intervention: Fruit intake
Number of subjects: 986
Study 33568188 — intervention group
Group type: EXPERIMENTAL
Intervention: Heuristic cadence thresholds of ≥100 steps/min
Number of subjects: 157
Study 33568188 — intervention group
Group type: EXPERIMENTAL
Intervention: Heuristic cadence thresholds of ≥130 steps/min
Number of subjects: 157
Study 33568188 — intervention group
Group type: EXPERIMENTAL
Intervention: Optimal cadence thresholds for moderate intensity
Number of subjects: 157
Study 33568188 — intervention group
Group type: EXPERIMENTAL
Intervention: Optimal cadence thresholds for vigorous intensity
Number of subjects: 157
Study 33568188 — intervention group
Group type: EXPERIMENTAL
Intervention: ROC analysis cadence thresholds for moderate intensity
Number of subjects: 157
Study 33568188 — intervention group
Group type: EXPERIMENTAL
Intervention: ROC analysis cadence thresholds for vigorous intensity
Number of subjects: 157
Study 33568190 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostate Membrane Specific Antigen (PSMA) positron emission tomography (PET) and multiparametric MRI (mpMRI)
Number of subjects: 34
Study 33568190 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant or salvage radiation therapy (PORT)
Number of subjects: 34
Study 33568222 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple-negative breast cancer (TNBC) patients diagnosed before age 70, predominantly BRCA1-deficient cases (90% of 82 cases).
Number of subjects: 237
Study 33568222 — intervention group
Group type: EXPERIMENTAL
Intervention: Full TNBC cohort.
Number of subjects: 237
Study 33568222 — intervention group
Group type: EXPERIMENTAL
Intervention: TNBC patients across different genetic subtypes.
Number of subjects: 237
Study 33568222 — intervention group
Group type: EXPERIMENTAL
Intervention: Public WGS data for other breast cancer subgroups.
Number of subjects: 237
Study 33568344 — intervention group
Group type: EXPERIMENTAL
Intervention: Atezolizumab (anti-PD-L1), administered intravenously every 3 weeks until confirmed disease progression or loss of clinical benefit.
Number of subjects: 35
Study 33568344 — intervention group
Group type: EXPERIMENTAL
Intervention: Atezolizumab (anti-PD-L1)
Number of subjects: 35
Study 33568345 — intervention group
Group type: EXPERIMENTAL
Intervention: Crizotinib at the recommended phase II dose of 280 mg/m²
Number of subjects: 20
Study 33568350 — intervention group
Group type: EXPERIMENTAL
Intervention: Additional immune modulators (tumor necrosis factor-alpha inhibitor 77%, mycophenolate 23%) in addition to systemic steroids
Number of subjects: 26
Study 33568350 — intervention group
Group type: EXPERIMENTAL
Intervention: Additional immune modulators
Number of subjects: 26
Study 33568360 — intervention group
Group type: EXPERIMENTAL
Intervention: Statin therapy (10.8% at baseline, 46.5% moderate-intensity, 4.6% high-intensity)
Number of subjects: 288
Study 33568360 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined treatment (4.2% at baseline, increased to 41.6% at 3 months, decreased to 20.8% at 1 year, increased to 38.9% at 2 years)
Number of subjects: 288
Study 33568360 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibrates (8.3% at baseline)
Number of subjects: 288
Study 33568367 — intervention group
Group type: EXPERIMENTAL
Intervention: L-POCUS (lung point-of-care ultrasonography) performed within 48 hours following ED admission
Number of subjects: 0
Study 33568367 — intervention group
Group type: EXPERIMENTAL
Intervention: L-POCUS score assessment
Number of subjects: 0
Study 33568367 — intervention group
Group type: EXPERIMENTAL
Intervention: Second L-POCUS performed at day 5±3
Number of subjects: 0
Study 33568367 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment as recommended by WHO
Number of subjects: 0
Study 33568371 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based rehabilitation programme (H-RP) including smoking cessation, nutritional support, physiotherapy (at least one session/week), and home cycle-ergometry (at least three times/week).
Number of subjects: 50
Study 33568371 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based rehabilitation programme (H-RP) non-completion.
Number of subjects: 50
Study 33568371 — intervention group
Group type: EXPERIMENTAL
Intervention: Polypharmacy (n=24).
Number of subjects: 50
Study 33568371 — intervention group
Group type: EXPERIMENTAL
Intervention: Living alone (n=8).
Number of subjects: 50
Study 33568371 — intervention group
Group type: EXPERIMENTAL
Intervention: Long delay before starting the H-RP (n=18).
Number of subjects: 50
Study 33568372 — intervention group
Group type: EXPERIMENTAL
Intervention: Roux-en-Y gastric bypass surgery
Number of subjects: 0
Study 33568372 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative assessment factors
Number of subjects: 0
Study 33568403 — intervention group
Group type: EXPERIMENTAL
Intervention: Type 1 diabetes
Number of subjects: 144
Study 33568403 — intervention group
Group type: COMPARATOR
Intervention: Control subjects without diabetes
Number of subjects: 144
Study 33569002 — intervention group
Group type: EXPERIMENTAL
Intervention: Proposed biosimilar BAT1806
Number of subjects: 0
Study 33569002 — intervention group
Group type: COMPARATOR
Intervention: Reference Tocilizumab
Number of subjects: 0
Study 33569214 — intervention group
Group type: EXPERIMENTAL
Intervention: Etoposide capsules (25 mg/50 mg) as maintenance therapy, once a day for 20 days, every 28 days until disease progression.
Number of subjects: 92
Study 33569214 — intervention group
Group type: COMPARATOR
Intervention: Observation (non-maintenance therapy, NMT) group.
Number of subjects: 92
Study 33569214 — intervention group
Group type: EXPERIMENTAL
Intervention: Etoposide capsules (25 mg) in stage I.
Number of subjects: 92
Study 33569305 — intervention group
Group type: EXPERIMENTAL
Intervention: Immune checkpoint inhibitors (ICIs)
Number of subjects: 103
Study 33569305 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 103
Study 33569311 — intervention group
Group type: EXPERIMENTAL
Intervention: RRx-001 treatment in combination with a platinum doublet
Number of subjects: 14
Study 33569311 — intervention group
Group type: EXPERIMENTAL
Intervention: RRx-001 treatment
Number of subjects: 14
Study 33569343 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyanoacrylate
Number of subjects: 111
Study 33569343 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 111
Study 33569442 — intervention group
Group type: EXPERIMENTAL
Intervention: Capture-based targeted sequencing using various commercially-available panels
Number of subjects: 32
Study 33569442 — intervention group
Group type: EXPERIMENTAL
Intervention: Two- and three-tier classification systems based on TMB estimates
Number of subjects: 32
Study 33569446 — intervention group
Group type: EXPERIMENTAL
Intervention: MF30 asymmetric refractive MIOLs
Number of subjects: 70
Study 33569446 — intervention group
Group type: COMPARATOR
Intervention: ZMB00 all optic zone diffractive MIOLs
Number of subjects: 70
Study 33569469 — intervention group
Group type: EXPERIMENTAL
Intervention: CCC-ACS score (new point-based risk score)
Number of subjects: 62546
Study 33569469 — intervention group
Group type: EXPERIMENTAL
Intervention: CCC-ACS score
Number of subjects: 62546
Study 33569494 — intervention group
Group type: EXPERIMENTAL
Intervention: BI 1265162 single doses ≤1200 µg
Number of subjects: 0
Study 33569494 — intervention group
Group type: EXPERIMENTAL
Intervention: BI 1265162 multiple doses of 600 µg
Number of subjects: 0
Study 33569494 — intervention group
Group type: EXPERIMENTAL
Intervention: BI 1265162
Number of subjects: 0
Study 33569501 — intervention group
Group type: EXPERIMENTAL
Intervention: Respiratory Symptoms Questionnaire (RSQ)
Number of subjects: 1530
Study 33569501 — intervention group
Group type: EXPERIMENTAL
Intervention: RSQ items
Number of subjects: 1530
Study 33569563 — intervention group
Group type: EXPERIMENTAL
Intervention: Mental Component Score (MCS) for participants who later developed dementia (mean± SD: 53.9±9.5)
Number of subjects: 2746
Study 33569563 — intervention group
Group type: COMPARATOR
Intervention: Physical Component Score (PCS) at baseline for dementia (49.3±7.9) vs. non-dementia (49.8±7.8)
Number of subjects: 2746
Study 33569563 — intervention group
Group type: EXPERIMENTAL
Intervention: MCS as an indicator for eventual dementia diagnosis
Number of subjects: 2746
Study 33569563 — intervention group
Group type: EXPERIMENTAL
Intervention: 10-unit increase in MCS
Number of subjects: 2746